358 reports of this reaction
1.9% of all POLATUZUMAB VEDOTIN reports
#16 most reported adverse reaction
DIFFUSE LARGE B CELL LYMPHOMA is the #16 most commonly reported adverse reaction for POLATUZUMAB VEDOTIN, manufactured by Genentech, Inc.. There are 358 FDA adverse event reports linking POLATUZUMAB VEDOTIN to DIFFUSE LARGE B CELL LYMPHOMA. This represents approximately 1.9% of all 19,009 adverse event reports for this drug.
Patients taking POLATUZUMAB VEDOTIN who experience diffuse large b cell lymphoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIFFUSE LARGE B CELL LYMPHOMA is a less commonly reported adverse event for POLATUZUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to diffuse large b cell lymphoma, the following adverse reactions have been reported for POLATUZUMAB VEDOTIN:
The following drugs have also been linked to diffuse large b cell lymphoma in FDA adverse event reports:
DIFFUSE LARGE B CELL LYMPHOMA has been reported as an adverse event in 358 FDA reports for POLATUZUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIFFUSE LARGE B CELL LYMPHOMA accounts for approximately 1.9% of all adverse event reports for POLATUZUMAB VEDOTIN, making it a notable side effect.
If you experience diffuse large b cell lymphoma while taking POLATUZUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.